title: Effects of oligoelements Se, Zn, and Mn plus Lachesis muta venom in experimental scleroderma.
abstract: Scleroderma, sclerosis of the skin, is a severe autoimmune disease refractant to all kind of treatments. To study the in vivo effects of a combination of three oligoelements selenium (Se), zinc (Zn), and manganese (Mn) plus Lachesis muta venom (O-LM) on the bleomycin (BLM)-induced scleroderma mouse experimental model. C3H mice were randomly divided into four groups: control (phosphate-buffered saline (PBS)), O-LM, BLM, and BLM + O-LM. All administrations were performed subcutaneously into the back of mice. BLM was injected 5 days per week for three consecutive weeks and O-LM was administered simultaneously with BLM from the beginning of the experiments and lasted for 3 weeks after the final BLM or PBS injection (for O-LM and BLM + O-LM groups), when animals were sacrificed and histopathological, immunohistochemical, thiobarbituric acid reactive species (TBARS) evaluation, and autoantibodies detection were determined. O-LM significantly reduced BLM-induced enhanced dermal thickness (605 ± 47 vs. 956 ± 59 μm, P < 0.01), collagen deposition, and mast cells infiltration (43.1 ± 1.0 vs. 102 ± 14.1 mast cells, P < 0.05). O-LM administration significantly blocked BLM-induced oxidative damage and the enhanced immunoreactive fibroblasts for α-smooth muscle actin while reduced BLM-induced autoantibodies that strongly react mainly with skin and spleen. O-LM significantly reduced BLM-induced scleroderma through the modulation of antioxidant and immunological pathways.
authors.affiliation: Institute of Immunooncology, 3200 Córdoba Av., 1187, Buenos Aires, Argentina.
authors.forename: Ernesto J V
authors.initials: EJ
authors.lastname: Crescenti
authors.forename: Vanina A
authors.initials: VA
authors.lastname: Medina
authors.forename: Lorena A
authors.initials: LA
authors.lastname: Sambuco
authors.forename: Graciela A
authors.initials: GA
authors.lastname: Cremaschi
authors.forename: Ana M
authors.initials: AM
authors.lastname: Genaro
authors.forename: Graciela P
authors.initials: GP
authors.lastname: Cricco
authors.forename: Gabriela A
authors.initials: GA
authors.lastname: Martín
authors.forename: Eduardo
authors.initials: E
authors.lastname: Valli
authors.forename: Diego J
authors.initials: DJ
authors.lastname: Martinel Lamas
authors.forename: Juan C
authors.initials: JC
authors.lastname: Perazzo
authors.forename: Elena S
authors.initials: ES
authors.lastname: Rivera
authors.forename: Rosa M
authors.initials: RM
authors.lastname: Bergoc
mesh_terms: D000818:Animals; D000975:Antioxidants / Q000378:metabolism; D001323:Autoantibodies / Q000097:blood; D001761:Bleomycin / Q000494:pharmacology; D002452:Cell Count; D002470:Cell Survival / Q000187:drug effects; D003435:Crotalid Venoms / Q000008:administration & dosage / Q000627:therapeutic use* / Q000633:toxicity; D004195:Disease Models, Animal; D004359:Drug Therapy, Combination; D008345:Manganese / Q000008:administration & dosage / Q000627:therapeutic use* / Q000633:toxicity; D008407:Mast Cells / Q000187:drug effects / Q000276:immunology / Q000473:pathology; D051379:Mice; D008807:Mice, Inbred BALB C; D008809:Mice, Inbred C3H; D009928:Organ Specificity; D018384:Oxidative Stress / Q000187:drug effects; D012595:Scleroderma, Systemic / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D012643:Selenium / Q000008:administration & dosage / Q000627:therapeutic use* / Q000633:toxicity; D012867:Skin / Q000187:drug effects* / Q000276:immunology / Q000473:pathology; D015032:Zinc / Q000008:administration & dosage / Q000627:therapeutic use* / Q000633:toxicity
chemical_list: D000975:Antioxidants; D001323:Autoantibodies; D003435:Crotalid Venoms; C072644:Lachesis venom; D001761:Bleomycin; D008345:Manganese; D012643:Selenium; D015032:Zinc